Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 11/20 | 0.57 |
| ▸ | BDKRB2 | P30411 | 2/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 2/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9603360 | 0.89 | AGTR2 (0.59) | AGTR2BDKRB2MMP9CTSLCTSB | |
| SCHEMBL9033443 | 0.89 | AGTR2 (0.59) | AGTR2BDKRB2MMP9CTSLCTSB | |
| SCHEMBL9033440 | 0.89 | AGTR2 (0.59) | AGTR2BDKRB2MMP9CTSLCTSB | |
| SCHEMBL3784713 | 0.89 | AGTR2 (0.59) | AGTR2BDKRB2MMP9CTSLCTSB | |
| SCHEMBL27224005 | 0.89 | AGTR2 (0.59) | AGTR2BDKRB2MMP9CTSLCTSB | |
| SCHEMBL5635251 | 0.86 | AGTR2 (0.57) | AGTR2BDKRB2MMP9CTSLCTSB | |
| SCHEMBL5635255 | 0.86 | AGTR2 (0.57) | AGTR2BDKRB2MMP9CTSLCTSB | |
| SCHEMBL6515997 | 0.85 | AGTR2 (0.56) | AGTR2BDKRB2 | |
| SCHEMBL15241314 | 0.85 | AGTR2 (0.56) | AGTR2BDKRB2 | |
| SCHEMBL29921 | 0.85 | AGTR2 (0.56) | AGTR2BDKRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148242-B2 | N-formyl hydroxylamine compounds, compositions and methods of use | NOVARTIS AG (CH) | 2006-12-12 | — | — | US | disclosed |
| EP-1401828-B1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | VICURON PHARM INC (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1401828-A1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | Vicuron Pharmaceuticals, Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030045479-A1 | Novel N-formyl hydroxylamine compounds, compositions and methods of use | VICURON HOLDINGS LLC | 2003-03-06 | — | — | US | disclosed |
| WO-2002102790-A1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | VICURON PHARMACEUTICALS INC. (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045479-A1 | Novel N-formyl hydroxylamine compounds, compositions and methods of use | PDF, HNMT, AADAC | AGTR2 3606/4885BDKRB2 1770/4885MMP9 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.